Navigation
banner

Ocular Diseases Drug Discovery

2018-01-242018-02-062017-11-20
EARLY BIRD DISCOUNT! Register by Feb 06, 2018 to receive 10% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


MENTORS
Jonca Bull

Jonca Bull
VP, Regulatory Consulting; Ophthalmology Therapeutic Area Director
PPD
Jonca Bull
VP, Regulatory Consulting; Ophthalmology Therapeutic Area Director
PPD
 
About Mentor:
Jerry Cagle

Jerry Cagle
Independent Pharmaceuticals Professional
Former VP, R&D, Alcon
Jerry Cagle
Independent Pharmaceuticals Professional
Former VP, R&D, Alcon
 
About Mentor:

Dr. Cagle is a longtime ophthalmic industry executive with a broad range of scientific and operational experience gained over the past four decades.  After completng graduate studies, Dr. Cagle joined the Faculty at The Ohio State University.  Three years later, in 1976, he moved to Alcon Laboratories as Secton Head,  R&D Microbiology.  He led development of the first proprietary product at Alcon, an antibiotic.  In turn, he took on additional responsibilities as Vice President(VP)  of Clinical Research, VP Regulatory Affairs and then VP Product Development.  In 1996, he was named Alcon's Senior Vice President for Global R&D.  Since leaving Alcon in 2009, Dr. Cagle has served as a Director for Aerie Pharmaceuticals, Clearside Biomedical, GrayBug Vision, AC Immune, Novaliq and Nacuity.  He has also given time to Foundation Fighting Blindness to help establish the organization's clinical development capability.  

Emmett Cunningham

Emmett Cunningham
Partner
Clarus Ventures
Emmett Cunningham
Partner
Clarus Ventures
 
About Mentor:

Dr. Cunningham joined Clarus in 2006 with extensive experience in the biomedical and biopharmaceutical sectors. Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc (NYSE: PFE), where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology.

Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications.  He is Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001.   Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute.  He completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in London, and a fellowship in public health ophthalmology at the Wilmer Eye Institute in Baltimore.

Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit, a well-attended symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery and the American Society of Retinal Surgeons. The OIS brings together leading companies, clinicians, academics and investors in the ophthalmology space.

Dr. Cunningham represents Clarus on the Board of Directors of Annexon BiosciencesGraybug VisionRestoration Robotics, and SFJ Pharmaceuticals Group. He is a Board observer for Lumos Pharma and is on the Scientific Advisory Board of Aerie Pharmaceuticals (NASDAQ: AERI).

Previous Directorships include Neomend (acquired by Bard) and SARcode Biosciences (acquired by Shire). Additionally, he was Board Observer for AvillionFerrokin (acquired by Shire), Ophthotech (NASDAQ: OPHT), Pearl Therapeutics (acquired by AstraZeneca), and was a member of the Scientific Advisory Board for ESBATech (acquired by Alcon).  

Mala Dutta

Mala Dutta
Lead, Office of Translational Research
NEI, NIH
Mala Dutta
Lead, Office of Translational Research
NEI, NIH
 
About Mentor:

Mala Dutta completed her graduate studies in Immunology and T-cell signaling from the National Human Genome Research Institute (NHGRI), NIH, under the NIH-GWU Partnership Program. After brief post-doctoral research, she joined the Technology Transfer and Intellectual Property Office (TTIPO) at the National Institute of Allergy and Infectious Diseases (NIAID) as a Technology Development Specialist. She came on board the National Eye Institute’s Office of Translational Research as a Presidential Management Fellow and now leads the office in its technology development, collaboration, translational and inter-agency initiatives.

Cristina Kenney

Cristina Kenney
Professor & Director, Ophthalmology Research
UC Irvine
Cristina Kenney
Professor & Director, Ophthalmology Research
UC Irvine
 
About Mentor:
Carl Romano

Carl Romano
Executive Director, Ophthalmology
Regeneron
Carl Romano
Executive Director, Ophthalmology
Regeneron
 
About Mentor: